Tyk2 as a target for immune regulation in human viral/bacterial pneumonia

European Respiratory Journal

Volumn 50, Issue 1, 2017, Pages

  Berg, Johanna ^a,b   Zscheppang, Katja ^a   Fatykhova, Diana ^a   Tönnies, Mario ^c   Bauer, Torsten T ^c   Schneider, Paul ^d   Neudecker, Jens ^a   Rückert, Jens C ^a   Eggeling, Stephan ^e   Schimek, Maria ^e   Gruber, Achim D ^f   Suttorp, Norbert ^a   Hippenstiel, Stefan ^a   Hocke, Andreas C ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

^c Chest Hospital Heckeshorn   (Germany)

^d DRK Clinics   (Germany)

^e Nuclear Medicine   (Germany)

^f FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; INTERLEUKIN 1BETA; PROTEIN KINASE TYK2; IL1B PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; TYK2 PROTEIN, HUMAN;

ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CONTROLLED STUDY; CYTOKINE RELEASE; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREGULATION; INFLUENZA A (H3N2); INFLUENZA A VIRUS (H3N2); INNATE IMMUNITY; LUNG ALVEOLUS; LUNG ALVEOLUS EPITHELIUM CELL; LUNG ALVEOLUS MACROPHAGE; LUNG PARENCHYMA; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VIRUS PNEUMONIA; VIRUS STRAIN; ANTAGONISTS AND INHIBITORS; BACTERIAL PNEUMONIA; DRUG EFFECT; IMMUNOLOGY; INFLUENZA; INFLUENZA A VIRUS; LUNG; METABOLISM; STAPHYLOCOCCUS INFECTION;

GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; INTERFERONS; INTERLEUKIN-1BETA; LUNG; PNEUMONIA, BACTERIAL; STAPHYLOCOCCAL INFECTIONS; TYK2 KINASE;

EID: 85026198567     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01953-2016     Document Type: Article

References (52)

1. Austrian R, Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964; 60: 759-776.
2. Ewig S, Birkner N, Strauss R, et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 2009; 64: 1062-1069.
3. Smith AM, McCullers JA. Secondary bacterial infections in influenza virus infection pathogenesis. Curr Top Microbiol Immunol 2014; 385: 327-356.
4. Robinson KM, Kolls JK, Alcorn JF. The immunology of influenza virus-associated bacterial pneumonia. Curr Opin Immunol 2015; 34: 59-67.
5. Shahangian A, Chow EK, Tian X, et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest 2009; 119: 1910-1920.
6. Li W, Moltedo B, Moran TM. Type I interferon induction during influenza virus infection increases susceptibility to secondary Streptococcus pneumoniae infection by negative regulation of γδ T cells. J Virol 2012; 86: 12304-12312.
7. Sun K, Metzger DW. Inhibition of pulmonary antibacterial defense by interferon-γ during recovery from influenza infection. Nat Med 2008; 14: 558-564.
8. Eigenbrod T, Bode KA, Dalpke AH. Early inhibition of IL-1β expression by IFN-γ is mediated by impaired binding of NF-κB to the IL-1β promoter but is independent of nitric oxide. J Immunol 2013; 190: 6533-6541.
9. Guarda G, Braun M, Staehli F, et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 2011; 34: 213-223.
10. Masters SL, Mielke LA, Cornish AL, et al. Regulation of interleukin-1β by interferon-γ is species specific, limited by suppressor of cytokine signalling 1 and influences interleukin-17 production. EMBO Rep 2010; 11: 640-646.
11. Kafka D, Ling E, Feldman G, et al. Contribution of IL-1 to resistance to Streptococcus pneumoniae infection. Int Immunol 2008; 20: 1139-1146.
12. Robinson KM, Choi SM, McHugh KJ, et al. Influenza A exacerbates Staphylococcus aureus pneumonia by attenuating IL-1β production in mice. J Immunol 2013; 191: 5153-5159.
13. Aman MJ, Keller U, Derigs G, et al. Regulation of cytokine expression by interferon-α in human bone marrow stromal cells: Inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist. Blood 1994; 84: 4142-4150.
14. Göllner G, Aman MJ, Steffens HP, et al. Interferon-α (IFN-α) inhibits granulocyte-macrophage colony-stimulating factor (GM-CSF) expression at the post-transcriptional level in murine bone marrow stromal cells. Br J Haematol 1995; 91: 8-14.
15. Huang FF, Barnes PF, Feng Y, et al. GM-CSF in the lung protects against lethal influenza infection. Am J Respir Crit Care Med 2011; 184: 259-268.
16. Huang H, Li H, Zhou P, et al. Protective effects of recombinant human granulocyte macrophage colony stimulating factor on H1N1 influenza virus-induced pneumonia in mice. Cytokine 2010; 51: 151-157.
17. Sever-Chroneos Z, Murthy A, Davis J, et al. GM-CSF modulates pulmonary resistance to influenza A infection. Antiviral Res 2011; 92: 319-328.
18. Unkel B, Hoegner K, Clausen BE, et al. Alveolar epithelial cells orchestrate DC function in murine viral pneumonia. J Clin Invest 2012; 122: 3652-3664.
19. LeVine AM, Reed JA, Kurak KE, et al. GM-CSF-deficient mice are susceptible to pulmonary group B streptococcal infection. J Clin Invest 1999; 103: 563-569.
20. Standiford LR, Standiford TJ, Newstead MJ, et al. TLR4-dependent GM-CSF protects against lung injury in Gram-negative bacterial pneumonia. Am J Physiol Lung Cell Mol Physiol 2012; 302: L447-L454.
21. Steinwede K, Tempelhof O, Bolte K, et al. Local delivery of GM-CSF protects mice from lethal pneumococcal pneumonia. J Immunol 2011; 187: 5346-5356.
22. Herold S, Hoegner K, Vadász I, et al. Inhaled granulocyte/macrophage colony-stimulating factor as treatment of pneumonia-associated acute respiratory distress syndrome. Am J Respir Crit Care Med 2014; 189: 609-611.
23. Paine R, Standiford TJ, Dechert RE, et al. A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury. Crit Care Med 2012; 40: 90-97.
24. Hocke AC, Becher A, Knepper J, et al. Emerging human Middle East respiratory syndrome coronavirus causes widespread infection and alveolar damage in human lungs. Am J Respir Crit Care Med 2013; 188: 882-886.
25. Elbert KJ, Schäfer UF, Schäfers HJ, et al. Monolayers of human alveolar epithelial cells in primary culture for pulmonary absorption and transport studies. Pharm Res 1999; 16: 601-608.
26. Weinheimer VK, Becher A, Tönnies M, et al. Influenza A viruses target type II pneumocytes in the human lung. J Infect Dis 2012; 206: 1685-1694.
27. Szymanski KV, Toennies M, Becher A, et al. Streptococcus pneumoniae-induced regulation of cyclooxygenase-2 in human lung tissue. Eur Respir J 2012; 40: 1458-1467.
28. Smith MW, Schmidt JE, Rehg JE, et al. Induction of pro- and anti-inflammatory molecules in a mouse model of pneumococcal pneumonia after influenza. Comp Med 2007; 57: 82-89.
29. Cakarova L, Marsh LM, Wilhelm J, et al. Macrophage tumor necrosis factor-α induces epithelial expression of granulocyte-macrophage colony-stimulating factor: Impact on alveolar epithelial repair. Am J Respir Crit Care Med 2009; 180: 521-532.
30. Lee B, Robinson KM, McHugh KJ, et al. Influenza-induced type I interferon enhances susceptibility to Gram-negative and Gram-positive bacterial pneumonia in mice. Am J Physiol Lung Cell Mol Physiol 2015; 309: L158-L167.
31. Van Reeth K. Cytokines in the pathogenesis of influenza. Vet Microbiol 2000; 74: 109-116.
32. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005; 5: 375-386.
33. Jewell NA, Cline T, Mertz SE, et al. Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. J Virol 2010; 84: 11515-11522.
34. Wu W, Zhang W, Duggan ES, et al. RIG-I and TLR3 are both required for maximum interferon induction by influenza virus in human lung alveolar epithelial cells. Virology 2015; 482: 181-188.
35. Sutejo R, Yeo DS, Myaing MZ, et al. Activation of type I and III interferon signalling pathways occurs in lung epithelial cells infected with low pathogenic avian influenza viruses. PLoS One 2012; 7: E33732.
36. Wu W, Zhang W, Booth JL, et al. Influenza A(H1N1)pdm09 virus suppresses RIG-I initiated innate antiviral responses in the human lung. PLoS One 2012; 7: E49856.
37. Killip MJ, Fodor E, Randall RE. Influenza virus activation of the interferon system. Virus Res 2015; 209: 11-22.
38. Wallace WA, Howie SE. Immunoreactive interleukin 4 and interferon-γ expression by type II alveolar epithelial cells in interstitial lung disease. J Pathol 1999; 187: 475-480.
39. Hennet T, Ziltener HJ, Frei K, et al. A kinetic study of immune mediators in the lungs of mice infected with influenza A virus. J Immunol 1992; 149: 932-939.
40. Chujor CS, Klein L, Lam C. Selective inhibition of interleukin-1β gene expression in activated RAW 264.7 macrophages by interferon-γ. Eur J Immunol 1996; 26: 1253-1259.
41. De Boer ML, Hu J, Kalvakolanu DV, et al. IFN-γ inhibits lipopolysaccharide-induced interleukin-1β in primary murine macrophages via a Stat1-dependent pathway. J Interferon Cytokine Res 2001; 21: 485-494.
42. Quinton LJ. GM-CSF: A double dose of protection during pneumonia. Am J Physiol Lung Cell Mol Physiol 2012; 302: L445-L446.
43. Subramaniam R, Hillberry Z, Chen H, et al. Delivery of GM-CSF to protect against influenza pneumonia. PLoS One 2015; 10: E0124593.
44. Mir-Kasimov M, Sturrock A, McManus M 3rd, et al. Effect of alveolar epithelial cell plasticity on the regulation of GM-CSF expression. Am J Physiol Lung Cell Mol Physiol 2012; 302: L504-L511.
45. Crane IJ, Wallace CA, Forrester JV. Regulation of granulocyte-macrophage colony-stimulating factor in human retinal pigment epithelial cells by IL-1β and IFN-γ. Cell Immunol 2001; 209: 132-139.
46. Davidson S, McCabe TM, Crotta S, et al. IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment. EMBO Mol Med 2016; 8: 1099-1112.
47. Radwan M, Stiefvater R, Grunert T, et al. Tyrosine kinase 2 controls IL-1β production at the translational level. J Immunol 2010; 185: 3544-3553.
48. Menet CJ. Toward selective TYK2 inhibitors as therapeutic agents for the treatment of inflammatory diseases. Pharm Pat Anal 2014; 3: 449-466.
49. Mallia P, Johnston SL. Influenza infection and COPD. Int J Chron Obstruct Pulmon Dis 2007; 2: 55-64.
50. Sehatzadeh S. Influenza and pneumococcal vaccinations for patients with chronic obstructive pulmonary disease (COPD): An evidence-based review. Ont Health Technol Assess Ser 2012; 12: 1-64.
51. Torres A, Peetermans WE, Viegi G, et al. Risk factors for community-acquired pneumonia in adults in Europe: A literature review. Thorax 2013; 68: 1057-1065.
52. Müllerova H, Chigbo C, Hagan GW, et al. The natural history of community-acquired pneumonia in COPD patients: A population database analysis. Respir Med 2012; 106: 1124-1133.